http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 26 May 2026 08:58:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+25/26546662.html si-local-file:///var/storage/secattach/20260526/26546662.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+25/26546662.html Tue, 26 May 2026 08:58:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+25/26546662.html si-local-file:///var/storage/secattach/20260526/26546662.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+25/26546662.html Tue, 26 May 2026 08:58:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cardiol+Therapeutics+++++++++++++++++++Filed+by%3A+MMCAP+International+Inc.+SPC/26506580.html si-local-file:///var/storage/secattach/20260515/26506580.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cardiol+Therapeutics+++++++++++++++++++Filed+by%3A+MMCAP+International+Inc.+SPC/26506580.html Fri, 15 May 2026 16:35:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cardiol+Therapeutics+++++++++++++++++++Filed+by%3A+MMCAP+International+Inc.+SPC/26506580.html si-local-file:///var/storage/secattach/20260515/26506580.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cardiol+Therapeutics+++++++++++++++++++Filed+by%3A+MMCAP+International+Inc.+SPC/26506580.html Fri, 15 May 2026 16:35:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+14/26490029.html si-local-file:///var/storage/secattach/20260514/26490029.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+14/26490029.html Thu, 14 May 2026 07:38:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+14/26490029.html si-local-file:///var/storage/secattach/20260514/26490029.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+14/26490029.html Thu, 14 May 2026 07:38:00 -0400 CRDL O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual <span>BioConnect Investor Conference</span> at the NASDAQ in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>, on <chron>May 19, 2026</chron>, at <chron>1:30 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html Thu, 14 May 2026 07:27:00 -0400 A.09642568 CRDL CRDL O.20371933 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual <span>BioConnect Investor Conference</span> at the NASDAQ in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>, on <chron>May 19, 2026</chron>, at <chron>1:30 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html Thu, 14 May 2026 07:27:00 -0400 A.09642568 CRDL CRDL O.20371933 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual <span>BioConnect Investor Conference</span> at the NASDAQ in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>, on <chron>May 19, 2026</chron>, at <chron>1:30 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html Thu, 14 May 2026 07:27:00 -0400 A.09642568 CRDL CRDL O.20371933 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual <span>BioConnect Investor Conference</span> at the NASDAQ in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>, on <chron>May 19, 2026</chron>, at <chron>1:30 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html Thu, 14 May 2026 07:27:00 -0400 A.09642568 CRDL CRDL O.20371933 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual <span>BioConnect Investor Conference</span> at the NASDAQ in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>, on <chron>May 19, 2026</chron>, at <chron>1:30 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html Thu, 14 May 2026 07:27:00 -0400 A.09642568 CRDL CRDL O.20371933 O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual <span>BioConnect Investor Conference</span> at the NASDAQ in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>, on <chron>May 19, 2026</chron>, at <chron>1:30 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html Thu, 14 May 2026 07:27:00 -0400 A.09642568 CRDL CRDL O.20371933 O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual <span>BioConnect Investor Conference</span> at the NASDAQ in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>, on <chron>May 19, 2026</chron>, at <chron>1:30 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html Thu, 14 May 2026 07:27:00 -0400 A.09642568 CRDL CRDL O.20371933 O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual <span>BioConnect Investor Conference</span> at the NASDAQ in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>, on <chron>May 19, 2026</chron>, at <chron>1:30 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html Thu, 14 May 2026 07:27:00 -0400 A.09642568 CRDL CRDL O.20371933 O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual <span>BioConnect Investor Conference</span> at the NASDAQ in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>, on <chron>May 19, 2026</chron>, at <chron>1:30 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html Thu, 14 May 2026 07:27:00 -0400 A.09642568 CRDL CRDL O.20371933 O.40774130 http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO</location></span>, <span class="legendSpanClass"><chron>May 14, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("<b>Cardiol</b>" or the "<b>Company</b>"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 4th Annual <span>BioConnect Investor Conference</span> at the NASDAQ in <location value="LU/us.ny.nyc" idsrc="xmltag.org" >New York, NY</location>, on <chron>May 19, 2026</chron>, at <chron>1:30 p.m. EDT</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Cardiol+Therapeutics+to+Participate+in+Fireside+Chat+at+H.C.+Wainwright+4th+Annual+BioConnect+Investor+Conference+at+the+NASDAQ/26489880.html Thu, 14 May 2026 07:27:00 -0400 A.09642568 CRDL CRDL O.20371933 O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Mar+31/26470736.html si-local-file:///var/storage/secattach/20260511/26470736.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Mar+31/26470736.html Mon, 11 May 2026 17:27:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Mar+31/26470736.html si-local-file:///var/storage/secattach/20260511/26470736.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+Mar+31/26470736.html Mon, 11 May 2026 17:27:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+07/26448430.html si-local-file:///var/storage/secattach/20260507/26448430.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+07/26448430.html Thu, 07 May 2026 07:37:00 -0400 CRDL O.40774130 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+07/26448430.html si-local-file:///var/storage/secattach/20260507/26448430.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Cardiol+Therapeutics++++++For%3A+May+07/26448430.html Thu, 07 May 2026 07:37:00 -0400 CRDL O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+MAvERIC+Results+Accepted+for+Publication+in+the+Journal+of+the+American+Heart+Association/26448224.html <div class="xn-content"> <ul type="disc"><li><i>Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, </i><i>which recently surpassed 75% enrollment</i>.</li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO, ON</location></span>, <span class="legendSpanClass"><chron>May 7, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the <i><span>Journal of the American Heart Association</span> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+MAvERIC+Results+Accepted+for+Publication+in+the+Journal+of+the+American+Heart+Association/26448224.html Thu, 07 May 2026 07:27:00 -0400 A.09642568 A.19238921 CRDL CRDL O.16809625 O.20371933 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+MAvERIC+Results+Accepted+for+Publication+in+the+Journal+of+the+American+Heart+Association/26448224.html <div class="xn-content"> <ul type="disc"><li><i>Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, </i><i>which recently surpassed 75% enrollment</i>.</li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO, ON</location></span>, <span class="legendSpanClass"><chron>May 7, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the <i><span>Journal of the American Heart Association</span> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+MAvERIC+Results+Accepted+for+Publication+in+the+Journal+of+the+American+Heart+Association/26448224.html Thu, 07 May 2026 07:27:00 -0400 A.09642568 A.19238921 CRDL CRDL O.16809625 O.20371933 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+MAvERIC+Results+Accepted+for+Publication+in+the+Journal+of+the+American+Heart+Association/26448224.html <div class="xn-content"> <ul type="disc"><li><i>Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, </i><i>which recently surpassed 75% enrollment</i>.</li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO, ON</location></span>, <span class="legendSpanClass"><chron>May 7, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the <i><span>Journal of the American Heart Association</span> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+MAvERIC+Results+Accepted+for+Publication+in+the+Journal+of+the+American+Heart+Association/26448224.html Thu, 07 May 2026 07:27:00 -0400 A.09642568 A.19238921 CRDL CRDL O.16809625 O.20371933 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+MAvERIC+Results+Accepted+for+Publication+in+the+Journal+of+the+American+Heart+Association/26448224.html <div class="xn-content"> <ul type="disc"><li><i>Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, </i><i>which recently surpassed 75% enrollment</i>.</li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO, ON</location></span>, <span class="legendSpanClass"><chron>May 7, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the <i><span>Journal of the American Heart Association</span> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+MAvERIC+Results+Accepted+for+Publication+in+the+Journal+of+the+American+Heart+Association/26448224.html Thu, 07 May 2026 07:27:00 -0400 A.09642568 A.19238921 CRDL CRDL O.16809625 O.20371933 O.40774130 http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+MAvERIC+Results+Accepted+for+Publication+in+the+Journal+of+the+American+Heart+Association/26448224.html <div class="xn-content"> <ul type="disc"><li><i>Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, </i><i>which recently surpassed 75% enrollment</i>.</li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/ca.on.tornto" idsrc="xmltag.org" >TORONTO, ON</location></span>, <span class="legendSpanClass"><chron>May 7, 2026</chron></span> /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the <i><span>Journal of the American Heart Association</span> http://www.streetinsider.com/Press+Releases/Cardiol+Therapeutics%27+Phase+II+MAvERIC+Results+Accepted+for+Publication+in+the+Journal+of+the+American+Heart+Association/26448224.html Thu, 07 May 2026 07:27:00 -0400 A.09642568 A.19238921 CRDL CRDL O.16809625 O.20371933 O.40774130